Analysis of Therapeutic Targets and Prognostic Biomarkers of CXC Chemokines in Cervical Cancer Microenvironment

Wei na Kong  
Xinjiang Medical University Affiliated Tumor Hospital

Gang Zhao  
Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University

Hai xia Chen  
Xinjiang Medical University Affiliated Tumor Hospital

Wei na Wang  
Xinjiang Medical University Affiliated Tumor Hospital

Xiao qian Shang  
Xinjiang Medical University Affiliated Tumor Hospital

Qian nan Sun  
Xinjiang Medical University Affiliated Tumor Hospital

Fan Guo (✉️ 02569@xjmu.edu.cn)  
Xinjiang Medical University Affiliated Tumor Hospital  https://orcid.org/0000-0002-6552-8856

Xiu min Ma  
Xinjiang Medical University Affiliated Tumor Hospital  https://orcid.org/0000-0001-8011-7513

Primary research

Keywords: cervical cancer, CXC chemokine, Q-PCR, immunohistochemistry, prognosis, tumor microenvironment

Posted Date: May 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-495925/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License

Version of Record: A version of this preprint was published at Cancer Cell International on July 28th, 2021. See the published version at https://doi.org/10.1186/s12935-021-02101-9.
Abstract

Background: It is well known that the tumor microenvironment (TME) has been received an increasing number of attention. CXC chemokines could regulate immune cell transport and tumor cell activity, thus exerting anti-tumor immunity. However, studies on the expression and prognosis of CXC chemokines in cervical cancer (CC) are more limited.

Methods: The study investigated the role of CXC chemokines in the TME and prognosis of CC using public databases. Moreover, quantitative real-time PCR (Q-PCR) and immunohistochemistry (IHC) of CXC chemokines were performed to further verify.

Results: The transcriptional levels of CXCL1/3/5/6/8/9/10/11/13/14/16/17 in CC tissues were significantly elevated while the transcriptional levels of CXCL2/4/7/12 were significantly reduced. We reached a consistent conclusion that the expression of CXCL9/10/11/13 was verified by Q-PCR and IHC. Moreover, CC patients with low transcriptional levels of CXCL1/2/3/4/5/8 were significantly associated with longer overall survival (OS). Our data suggest that RELA, NFKB1, and SP1 are key transcription factors for CXC chemokines, and the LCK, LYN and PAK are CXC chemokine kinases targets. We found significant correlations among the expression of CXC chemokines and the infiltration of six types of immune cells.

Conclusions: We performed a comprehensive analysis of CXC chemokines via clinical data and some online tumor database. Our results may provide new idea for the selection of immunotherapeutic targets and prognostic biomarkers for cervical cancer.

Background

Deaths due to cancers are a growing threat to human survival [1]. Cervical cancer is one of the leading causes of cancer death in women. Globally, CC accounts for almost 12% of all female cancers, making it the fourth most common female cancer in the world [2, 3]. According to the 2018 Global Cancer Statistics report, the incidence and mortality of CC account for 6.6% and 7.5% of all female cancer patients, respectively [4]. There have been improvements in the early detection and treatment of CC, which has improved patient survival. Yet, CC still causes many deaths, and the median overall survival rate of advanced cervical cancer was only 16.8 months [5]. To improve patient survival in CC, it is crucial to identify novel therapeutic targets to guide individualized treatment and predict the survival outcomes of patients with CC. Recently, many researchers have explored the therapeutic targets of CC, especially kinase and immune checkpoint inhibitors, and some progress has been made [6]; however, this is far from sufficient, and more therapeutic targets and prognostic biomarkers must be identified.

Chemokines are a family of soluble proteins with low molecular weight (8–15 kDa) that not only play important roles in development, homeostasis and angiogenesis, but also are involved in autoimmune
diseases, in tumor-related inflammation and immunity, as well as tumor growth and metastasis [7, 8]. Chemokines are secreted by tumor cells, immune cells and stromal cells in the tumor microenvironment, which can regulate the transport of immune cells and the growth of lymphatic tissue, and thus regulating anti-tumor immune response [9]. As a subfamily of a large family of chemokines, CXC chemokines have also been found to play a role in tumor genesis, development and prognosis [10]. CXC chemokines are potential therapeutic targets and prognostic biomarkers for many types of tumors, including colorectal cancer, renal cell carcinoma and breast tumor, et al [11–13].

CXC chemokine is an important component in the TME. Although previous studies have confirmed the expression and role of some members of the CXC chemokine family in cervical cancer, there is a lack of comprehensive and systematic research. Therefore, it is still worth exploring CXC chemokines as a therapeutic target and prognostic marker of cervical cancer. In this study, public databases were used to explore the mRNA expression, prognosis, and related target or kinase pathways of CXC chemokine family in cervical cancer. Q-PCR and immunohistochemistry further verified the expression. In brief, this study complements the function of CXC chemokines in cervical cancer, suggesting that some CXC chemokines can be used as potential therapeutic targets and prognostic biomarkers for CC.

Materials And Methods

Study population

In this study, clinical data and pathological specimens were collected retrospectively, and the patient’s informed consent was obtained before the pathological specimens were collected. And cervical cancer and normal tissues specimens for Q-PCR and IHC analysis were obtained from patients undergoing surgery between January 1, 2017 and December 31, 2018 (N = 60). The current research work received approval from the Academic Committee of The Third Clinical Medical College of Xinjiang Medical University (affiliated Tumor Hospital) and was carried out in accordance with the rules put forward in the Declaration of Helsinki. This study had the relevant exemption certificate of informed consent issued by the Academic Committee. As the public dataset, neither ethics committee approval nor patient informed consent was needed for analyzing data.

Quantitative real-time PCR

Total RNA was isolated from normal tissues and tumor tissues using Trizol according to the manufacturer’s instructions. Extracted RNA was converted into cDNA using 5×primescript buffer, primescript RT enzyme mix I, oligo dT primer and random 6 mers. The quantitative real-time PCR was performed in a BioRad CFX96 Real-Time PCR Detection System machine in the presence of GAPDH, CXCL9, CXCL10, CXCL11 and CXCL13. Target gene transcription levels were measured and normalized to GAPDH expression. Statistical analysis was performed using Student’s t-test and Mann-Whitney U using Graphpad Prism 8 software (GraphPad Software). Differences with \( p \) values < 0.05 were considered statistically significant. The following primer sequences were used: GAPDH, 5’-GAAGGTGAAGGTCGGAGTC-3’ and 5’-GAAGATGGTGATGGGATTTC-3’; CXCL9, 5’-
TGAGAAAGGTCGCTGGTCC-3' and 5'-GGGCTTGGGCAAATTGTTT-3'; CXCL10, 5'-TGCCATTCTGATTGCTGCC-3' and 5'-TGCAGGTACAGCGTACAGTT-3'; CXCL11, 5'-CCCTGGGGTAAAAGCAGTGA-3' and 5'-TAAGCCTTTGCTGCTTCGAT-3'; CXCL13, 5'-CGACATCTCTGGTCTCATGC-3' and 5'-ACTGAGCTCTCTTTGGACACAT-3'.

**Immunohistochemistry**

Formalin-fixed paraffin-embedded surgical specimens were used for immunohistochemistry study. The cervical cancer sections were dried at 60°C for 2 hour, subsequently were dewaxed in xylene and graded alcohols, hydrated and washed in phosphate-buffered saline. After antigen repair was treated in a microwave oven (15 min in citrate buffer, pH 6), the endogenous peroxidase was inhibited by 3% H₂O₂ for 30 min, then the sections incubated with 10% normal goat serum for 40 min. Primary antibodies composed of rabbit anti-CXCL9 antibody (diluted 1:100, bs-2551R, Beijing Boiynthesis Biotechnology Co, Beijing, China), rabbit Anti-CXCL10 antibody (diluted 1:150, bs-1502R, Beijing Boiynthesis Biotechnology Co, Beijing, China), rabbit anti-CXCL11 antibody (diluted 1:150, bs-2552R, Beijing Boiynthesis Biotechnology Co, Beijing, China) and rabbit anti-CXCL13 antibody (diluted 1:100, bs-2553R, Beijing Boiynthesis Biotechnology Co, Beijing, China) were applied overnight in a moist room at 4°C. Then the tissues were incubated with secondary antibodies, stained with diaminobenzidine and counterstained with hematoxylin. Positive staining was evaluated using computer aided image analysis and Image J software. The average CXC chemokines infiltration were determined by two independent pathologists who did not know the patient's pathological and clinical status from three randomized fields.

**Transcription-related databases of CXC chemokines in patients of cervical cancer**

We used the public databases ONCOMINE (www.oncomine.org) [14], GEPIA (http://gepia.cancer-pku.cn/index.html) [15] and UALCAN (http://ualcan.path.uab.edu) [16] that could provide cancer RNA sequence data and clinical data to analyze the differential expression of CXC chemokines in cervical cancer and adjacent cancer or normal tissues by using Student's *t*-test. The cut-off of *p* value was 0.05. In ONCOMINE, the fold change was 2.0, and the gene rank was in the top 10%. In addition, we conducted a prognostic study of CXC chemokines in GEPIA through the Kaplan-Meier curve.

**cBioPortal**

cBioPortal (www.cbiomap.org) is an online open-access website that involves in exploring, visualizing, and analyzing multidimensional cancer genomics data [17]. Genetic alterations of CXC chemokines was obtained from cBioPortal based on TCGA database. 293 cervical squamous cell carcinoma samples (TCGA, PanCancer Atlas) were analyzed. mRNA expression z-scores (log RNA Seq V2 RSEM) were obtained using a z-score threshold of ± 2.0.

**CXC chemokines-related networks**
We studied the gene-association networks and protein-protein interaction (PPI) of CXC chemokines respectively by using GeneMANIA (http://www.genemania.org) [18], a website which could provide information on the protein and genetic interactions, pathways and co-expression of submitted genes, and the STRING database (https://string-db.org/) [19].

**Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis**

In this study, CXC chemokines were analyzed by GO, including biological processes (BP), cellular components (CC), molecular function (MF), and KEGG pathway enrichment on the website of DAVID 6.8 (https://david.ncifcrf.gov/home.jsp), which could clarify the biological functions of genes [20]. Then we visualized it with the "ggplot2" package of R software. \( P \)-value < 0.05 was considered to be statistically different.

**Target analysis of kinases and transcription factors**

The TRRUST (https://www.grnpedia.org/trrust/) database could provide transcription factor (TF)-target regulatory relationships [21]. Use the "LinkInterpreter" module in the LinkedOmics (http://www.linkedomics.org/) [22] database to obtain biological insights into kinase targets enrichment of CXC chemokines. We used TRRUST and LinkedOmics to perform TF and kinase targets analysis of CXC chemokines. Gene Set Enrichment Analysis (GSEA) was used to perform analyses with a minimum number of genes (size) of 3 and a simulation of 500. The results were analyzed by Spearman correlation test. The \( p \)-value cutoff was 0.05.

**TIMER database**

TIMER (https://cistrome.shinyapps.io/timer/) could provide a systematic assessment of the infiltration of different immune cells and their clinical effects [23]. This study used "Gene module" to evaluate the correlation between CXC chemokines level and immune cell infiltration in the tumor microenvironment.

**Results**

Abnormal expression of CXC chemokine in CC patients

In order to study the transcription levels of CXC chemokines between tumor and normal tissues in CC, we performed an analysis using the ONCOMINE, GEPIA and UALCAN database. Sixteen CXC chemokines were retrieved using the ONCOMINE database. The results are presented in Fig. 1 and Table 1. The transcriptional levels of CXCL1/3/8/9/10/11/13/16 in cervical cancer tissues were significantly elevated while the transcriptional levels of CXCL12/14 were significantly lower than that of normal cervical tissue. In GEPIA dataset, the results indicated that the expression levels of CXCL1/8/9/10/11/13/16/17 were increased while CXCL12 was reduced between tumor tissues and normal tissues in cervical (Fig. 2a). In UALCAN database, as expected, the transcriptional levels of CXCL6 \( (p = 1.18e-4) \), CXCL9 \( (p = 1.63e-12) \), CXCL10 \( (p = 7.77e-16) \), CXCL11 \( (p = 8.36e-13) \), CXCL13 \( (p = 2.81e-7) \) and CXCL17 \( (p = 1.74e-3) \) in cervical
tissues were significantly elevated (Fig. 2b-g). Taken together, these data suggest that these CXC chemokines play a significant role in the tumorigenesis and progression of cervical cancer.
Table 1
The significant changes of CXC chemokines expression in transcription level between different types of CC.

| TLR | Type                                                                 | Fold change | P-value | t-test | Reference                |
|-----|----------------------------------------------------------------------|-------------|---------|--------|--------------------------|
| CXCL1 | High Grade Cervical Squamous Intraepithelial Neoplasia Epithelia vs. Normal | 7.048       | 2.83e-5 | 6.446  | Zhai Cervix Statistics [24] |
|      | Cervical Squamous Cell Carcinoma Epithelia vs. Normal                | 4.462       | 1.33e-6 | 5.866  | Zhai Cervix Statistics [24] |
|      | Cervical Squamous Cell Carcinoma vs. Normal                          | 3.895       | 5.62e-5 | 4.166  | Scotto Cervix 2 Statistics [25] |
| CXCL3 | High Grade Cervical Squamous Intraepithelial Neoplasia Epithelia vs. Normal | 2.797       | 6.20e-4 | 4.111  | Zhai Cervix Statistics [24] |
| CXCL5 | High Grade Cervical Squamous Intraepithelial Neoplasia Epithelia vs. Normal | 5.994       | 0.002   | 4.393  | Zhai Cervix Statistics [24] |
| CXCL6 | High Grade Cervical Squamous Intraepithelial Neoplasia Epithelia vs. Normal | 2.976       | 0.003   | 3.969  | Zhai Cervix Statistics [24] |
| CXCL8 | Cervical Squamous Cell Carcinoma vs. Normal                          | 13.807      | 5.04e-9 | 6.765  | Scotto Cervix 2 Statistics [25] |
|      | Cervical Squamous Cell Carcinoma vs. Normal                          | 3.974       | 8.10e-8 | 7.474  | Biewenga Cervix Statistics [26] |
|      | Cervical Squamous Cell Carcinoma Epithelia vs. Normal                | 3.789       | 8.81e-5 | 4.318  | Zhai Cervix Statistics [24] |
| CXCL9 | Cervical Squamous Cell Carcinoma vs. Normal                          | 8.529       | 8.45e-9 | 11.614 | Biewenga Cervix Statistics [26] |
The expression of CXCL9/10/11/13 in cervical cancer tissues and normal tissues was also examined by Q-PCR (Fig. 3). We only verified CXCL9/10/11/13 because these factors were expressed in the intersection of the three common expression databases including ONCOMINE, GEPIA and UALCAN. CXCL9 ($p = 0.027$), CXCL10 ($p < 0.001$), CXCL11 ($p = 0.002$) and CXCL13 ($p < 0.001$) were significantly upregulated in cervical cancer tissues compared with normal tissues. We also carried out IHC for the purpose of testing the CXCL9/10/11/13 proteins expression in cervical cancer tissues as well as their counterparts. We found that CXCL9/10/11/13 proteins were more highly expressed in the cancer tissues than in the normal (Fig. 4). These were consistent with the findings in the database and further verified the transcriptional expression of CXCL9/10/11/13 in cervical cancer.

The prognostic value of CXC chemokines in cervical cancer
In order to evaluate the value of differentially expressed CXC chemokines in the progression of CC, we used GEPIA to evaluate the correlation between differentially expressed CXC chemokines and clinical outcomes. The low transcriptional levels of CXCL1 (\( p = 0.033 \)), CXCL2 (\( p = 0.046 \)), CXCL3 (\( p = 0.017 \)), CXCL4 (\( p = 0.027 \)), CXCL5 (\( p = 0.011 \)) and CXCL8 (\( p = 1.5\text{e-5} \)) were significantly associated with longer OS of CC patients (Fig. 5a-f). In addition, the value of differentially expressed CXC chemokines in the disease free survival (DFS) of cervical patients was also evaluated. We found that cervical cancer patients with low transcriptional level of CXCL3 (\( p = 0.018 \)) was significantly associated with longer DFS (Fig. 5g).

Analysis of genetic alteration, adjacent gene network and interaction of CXC chemokines in cervical cancer

We analyzed the genetic alterations of differentially expressed CXC chemokines by using the TCGA dataset in the cBioPortal. We found that high mutation rate of CXC chemokines (42%) was observed in CC patients. In the 293 sequenced cervical cancer patients, genetic alteration was found in 124 cervical cancer patients. As a result, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL6 and CXCL17 were altered in 6%, 3%, 4%, 4%, 6%, 5%, 5%, 5%, 6%, 6%, 5%, 5%, 6%, 5%, 7% and 6% of the cervical cancer samples, respectively (Fig. 6a). In addition, in order to explore the potential interactions of the differentially expressed CXC chemokines, we performed a protein-protein interaction (PPI) network analysis in STRING (Fig. 6b). The results revealed that the functions of these differentially expressed CXC chemokines were related to chemokine signaling pathways and inflammation response. In GeneMANIA website, the results also showed that the functions of differential expressed CXC chemokines were primarily related to cell chemotaxis, chemokine receptor binding, and chemokine activity (Fig. 6c).

Predicted functions and pathways of CXC chemokines in cervical cancer patients

The functions of differentially expressed CXC chemokines and their neighboring genes were analyzed using DAVID 6.8. The top 10 richest GO items are shown in Fig. 7a. GO term analysis showed that differentially expressed in correlation with CXC chemokines were located mainly in the extracellular space, extracellular region, cell, external side of plasma membrane and cell surface, where they participate chemotaxis, inflammatory response, monocyte chemotaxis, cellular response to interleukin-1 and immune response. They act as CCR chemokine receptor binding, CXCR chemokine receptor binding, heparin binding, chemokine receptor binding and chemoattractant activity. KEGG pathway analysis showed enrichment in the chemokine signaling pathway, cytokine-cytokine receptor interaction, rheumatoid arthritis, Toll-like receptor signaling pathway, TNF signaling pathway (Fig. 7b).

Kinase and transcription factor (TF) targets analysis in patients with cervical cancer

We used TRRUST and Linkedomics databases to explore the possible kinase and transcription factor targets of differential CXC chemokines in the cervical cancer microenvironment. We found that three transcription factors (RELA, NFKB1, and SP1) were associated with the regulation of CXC chemokines in the TRRUST (Table 2). RELA and NFKB1 were the key transcription factors for CXCL1/2/5/8/10/12. And
SP1 was the key transcription factor for CXCL1/5/14. We identified the top two kinase targets of CXC chemokines from the LinkedOmics database (Table 3). ATR and CHUK were the top two targets in the CXCL1 kinase-target network. Components of the CXCL2 kinase-target network were mainly associated with RPS6KB1 and ATM. GRK6 and ATM were suggested as the targets for the CXCL3 kinase-target network. PAK2 and PAK3 were primarily related to CXCL5. DAPK1 and EGFR were the top two targets in the CXCL6 kinase-target network. Components of the CXCL9 kinase-target network were mainly associated with ZAP70 and LCK. LYN and LCK were suggested as the targets for the CXCL10 and CXCL11 kinase-target network. RPS6KA4 and PLK3 were primarily related to CXCL12. LCK and SYK, and CDK1 and MAP3K8 were the top two targets in the CXCL13 and CXCL14 kinase-target networks, respectively. Components of the CXCL16 and CXCL17 kinase-target networks were mainly associated with LCK and LYN, as well as ADRBK1 and IGF1R.

Table 2
Key regulated factor of CXC chemokines in CC (TRRUST).

| Key TF | Description                                           | Regulated gene                      | P-value     | FDR     |
|--------|-------------------------------------------------------|-------------------------------------|-------------|---------|
| RELA   | v-rel reticuloendotheliosis viral oncogene homolog A (avian) | CXCL1, CXCL2, CXCL5, CXCL8, CXCL10, CXCL12 | 1.09e-07    | 1.71e-07 |
| NFKB1  | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | CXCL1, CXCL2, CXCL5, CXCL8, CXCL10, CXCL12 | 1.14e-07    | 1.71e-07 |
| SP1    | Sp1 transcription factor                              | CXCL1, CXCL5, CXCL14                | 0.00683     | 0.00683 |
Table 3
The Kinase target networks of CXC chemokines in CC (LinkedOmics).

| CXC chemokines | Enriched kinase target | Description                                      | Leading EdgeNum | P-value |
|----------------|------------------------|--------------------------------------------------|-----------------|---------|
| CXCL1          | Kinase_ATR             | ATR serine/threonine kinase                      | 16              | 0       |
|                | Kinase_CHUK            | conserved helix-loop-helix ubiquitoust kinase     | 10              | 0       |
| CXCL2          | Kinase_RPS6KB1         | ribosomal protein S6 kinase B1                   | 6               | 0       |
|                | Kinase_ATM             | ATM serine/threonine kinase                      | 38              | 0       |
| CXCL3          | Kinase_GRK6            | G protein-coupled receptor kinase 6              | 2               | 0       |
|                | Kinase_ATM             | ATM serine/threonine kinase                      | 37              | 0       |
| CXCL5          | Kinase_PAK2            | p21 (RAC1) activated kinase 2                    | 7               | 0       |
|                | Kinase_PAK3            | p21 (RAC1) activated kinase 3                    | 3               | 0       |
| CXCL6          | Kinase_DAPK1           | death associated protein kinase 1                | 6               | 0       |
|                | Kinase_EGFR            | epidermal growth factor receptor                 | 20              | 0       |
| CXCL9          | Kinase_ZAP70           | zeta chain of T-cell receptor associated protein kinase 70 | 4               | 0       |
|                | Kinase_LCK             | LCK proto-oncogene, Src family tyrosine kinase   | 23              | 0       |
| CXCL10         | Kinase_LYN             | LYN proto-oncogene, Src family tyrosine kinase   | 21              | 0       |
|                | Kinase_LCK             | LCK proto-oncogene, Src family tyrosine kinase   | 21              | 0       |
| CXCL11         | Kinase_LCK             | LCK proto-oncogene, Src family tyrosine kinase   | 22              | 0       |
|                | Kinase_LYN             | LYN proto-oncogene, Src family tyrosine kinase   | 21              | 0       |
| CXCL12         | Kinase_RPS6KA4         | ribosomal protein S6 kinase A4                   | 11              | 0       |
|                | Kinase_PLK3            | polo like kinase 3                               | 6               | 0       |
| CXCL13         | Kinase_LCK             | LCK proto-oncogene, Src family tyrosine kinase   | 22              | 0       |
|                | Kinase_SYK             | spleen associated tyrosine kinase                | 15              | 0       |
| CXCL14         | Kinase_CDK1            | cyclin dependent kinase 1                        | 74              | 0       |
|                | Kinase_MAP3K8           | mitogen-activated protein kinase kinase 8        | 7               | 0       |
Analysis of CXC chemokine immune cell infiltration in patients with cervical cancer

As a component of the TME, CXC chemokines are involved in inflammation responses and immune cell infiltration, thereby affecting the clinical outcome of cervical cancer patients. Therefore, we comprehensively explore the correlation between differentially expressed CXC chemokines and immune cell infiltration using the TIMER database (Fig. 8). There was a negative correlation between CXCL1 expression and the infiltration of CD4+ T cells (Cor = -0.201, \( p = 7.75\times10^{-4} \)), macrophages (Cor = -0.175, \( p = 3.41\times10^{-3} \)) and dendritics (Cor = -0.163, \( p = 6.61\times10^{-3} \)). The infiltration of CD4+ T cells was negatively associated with CXCL2 (Cor = -0.198, \( p = 9.10\times10^{-4} \)) and CXCL3 (Cor = -0.224, \( p = 1.76\times10^{-4} \)). CXCL4 expression was negatively associated with the infiltration of CD4+ T cells (Cor = -0.136, \( p = 2.37\times10^{-2} \)), and positively associated with the infiltration of macrophages (Cor = 0.128, \( p = 3.34\times10^{-2} \)). There was a positive correlation between the expression of CXCL9, CXCL10, CXCL11, CXCL13 and CXCL16, and the infiltration of CD8+ T cells, CD4+ T cells, neutrophils and dendritic cells (all \( p < 0.05 \)). There was a positive correlation between the expression of CXCL12, and the infiltration of B cells, CD4+ T cells, macrophages and dendritic cells (all \( p < 0.05 \)). CXCL14 expression was negatively associated with the infiltration of neutrophils (Cor = -0.198, \( p = 9.01\times10^{-4} \)), and positively associated with the infiltration of B cells (Cor = 0.125, \( p = 3.78\times10^{-2} \)) and macrophages (Cor = 0.123, \( p = 4.07\times10^{-2} \)). CXCL17 expression was positively associated with the infiltration of CD4+ T cells (Cor = 0.19, \( p = 1.48\times10^{-3} \)) and neutrophils (Cor = 0.174, \( p = 3.58\times10^{-3} \)).

Discussion

CC remains one of the major causes of cancer-related death among woman world-wide [1]. For patients with early cervical cancers, surgery or radiotherapy or a combination of both is recommended for the best cure rate [27, 28]. However, in most cases, the majority of patients with cervical cancer present with an advanced stage of disease, with limited access to adequate treatment. As a result, the mortality rates are still high [27]. Nowadays, an increasing number of studies have demonstrated the importance of a new type of regulation by epigenetics in specific genes in the progression of cervical cancer [29]. This provides new ideas for the treatment of cervical cancer. The present findings demonstrate that the CXC chemokines was correlated with survival of CC patients, indicating that CXC chemokines could be a potential therapeutic targets and prognostic biomarkers of CC.
Intercellular communication between CC cells and stromal cells affects the expression patterns of chemokines in various cell types, thus facilitating specific microenvironments for tumor invasion and metastasis. CXC chemokines' altered expression in malignancies dictates leukocyte recruitment and activation, angiogenesis, tumorigenesis, cancer cell proliferation, and metastasis in all the stages of the disease [30–32]. Studies have reported correlations between CXC chemokine, tumor microenvironment and tumor immunotherapy, suggesting that CXC chemokines may regulate tumor progression and immunotherapy effect [33]. However, the prognostic value and biological function of CXC chemokines in CC have not been comprehensively characterized.

We comprehensively analyzed the expression and function of CXC chemokines in cervical cancer by using public databases. This study found that the expression of CXCL1/3/5/6/8/9/10/11/13/14/16/17 was up-regulated in cervical cancer tissues, while the expression of CXCL2/4/7/12 was down-regulated. Q-PCR and IHC also showed that CXCL9/10/11/13 was highly expressed in cervical cancer tissues. In addition, CC patients with low transcription levels of CXCL1/2/3/4/5/8 had longer OS, while CC patients with low levels of CXCL3 had longer DFS. We also found that RELA, NFKB1 and SP1 are the key TFs for CXC chemokines, and LCK, LYN and ATM are the kinases targets of CXC chemokines. In brief, these data indicated that differentially expressed CXC chemokines may play an important role in CC.

Tumorigenesis and the progression of cervical cancer is a complex and multifaceted. Due to the significant differential expression of multiple chemokines in CC, we explored the molecular characteristics of these chemokines in CC. CXC chemokines differentially expressed in CC had frequent genetic alterations with a mutation rate of 42%, of which increased mRNA expression was the most alteration. The CCL family was associated with CXC chemokines neighboring alteration, including CCL1, CCL2, CCL8 and CCL21, etc. These CCL factors play different but similar functions in tumors. It has been reported that CCL1, CCL2 and CCL21 affect tumor metastasis and progression through direct or indirect interactions with lymph nodes [34–36]. CCL8 was independent prognostic factors in cervical cancer patients, and increased CCL8 secretion promoting tumor progression [37, 38].

Then via GO enrichment analysis and KEGG pathway enrichment analysis, we found that the functions of these genes are primarily related to the chemokine signaling pathway, cytokine-cytokine receptor interaction, and the Toll-like receptor signaling pathway. Studies have shown that chemokine signaling pathways play a key role in the proliferation, angiogenesis, immune evasion and metastasis of various cancers [39–41]. TLRs are type I intermembrane proteins, containing a leucinerich domain (that recognizes the PAMPs) and an intracellular domain that activates signal transduction. It has been demonstrated that TLR signaling pathways in tumor cells can affect cancer progression. Stimulation of TLRs in tumor cells fosters chronic inflammation that drives cancer cell proliferation, migration, and angiogenesis, and establishes a tumor microenvironment that impairs the immune system, thereby allowing tumors to establish themselves and to thrive [42, 43]. These data indicated that CXC chemokines differentially expressed in CC were potential therapeutic targets.
By analyzing the differential expression of CXC chemokines in cervical cancer, we found three key transcription factors (RELA, NFKB1 and SP1). RELA phosphorylation contributes to disease progression, especially inflammatory diseases and cancer, by regulating NF-κB signaling [44]. Some studies have revealed an association between elevated RELA expression and poor survival [45]. NFKB1 display increased inflammation and susceptibility to certain forms of DNA damage, leading to cancer, and a rapid ageing phenotype [46]. NFKB1 was a tumour suppressor by inhibiting cell proliferation, colony formation and migration in cervical cancer, while the mutation could weaken the tumour suppressing functions of NFKB1 [47]. Sp1 may contribute to radioresistance through inhibiting G2/M phase arrest by targeting CDK1, affecting the prognosis of patients [48]. Moreover, our data indicated that the SRC family tyrosine kinases (LCK, LYN) and PAK family kinase (PAK2, PAK3) were the probable targets of the differentially expressed CXC chemokines. These kinases are involved in tumor development and progression by regulating tumor cell proliferation, migration, invasion, and apoptosis [49–51]. In CC, differentially expressed CXC chemokines may affect tumor development and progression by regulating these kinases.

In the cervical cancer microenvironment, CXC chemokines could control the migration and localization of immune cells, and immune cells could be a factor of immunotherapy and clinical outcome by affecting tumor development and progression [52, 53]. In this study, we found a significant correlation between the expression of CXC chemokines and the infiltration of the six immune cell types, B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and dendritic cells. Previous studies have shown that the interaction of CD4 + T cell and CD8 + T cells influence the immune response and prognosis of tumors [54, 55]. Macrophages influence tumor development via interacting with tumor cells to induce lymphangiogenesis in CC [56]. These results indicated that CXC chemokines are not only as prognostic indicators, but also may reflect immune status.

In our study, experiment and several online bioinformatic platforms were systematically analyzed the expression, mutations, correlated genes, and prognostic value of CXC chemokines in CC. At the same time, there were some limitations in our study. First, a multicenter, prospective research is needed to validate the conclusions because our study is the retrospective design. Second, analysis on the transcriptional and translational level can reflect some aspects of immune status, but not global changes. Third, we should collect more clinical specimen data for experimental verification. Moreover, only the mRNA and protein expressions of CXCL9/10/11/13 were verified in the experiment, and more indicators should be further verified in the experiment.

Conclusions

In conclusion, we performed a comprehensive analysis of CXC chemokines via clinical data and some online tumor database. Patients with low transcriptional levels of CXCL1/2/3/4/5/8 were significantly associated with better prognosis. We hope our results could provide novel insights for the selection of immunotherapeutic targets and prognostic biomarkers for cervical cancer.

Abbreviations
Declarations

Acknowledgments

Thanks to Xinjiang Medical University for helping authors in manuscript. And we sincerely thank all the authors and study participants for their support in this study.

Author Contributions

WNK and FG conceived and designed the research. WNK, GZ, FG performed the experiments, interpreted the data and wrote the manuscript. HXC, WNW, XQS and QNS discussed the data and provided constructive suggestions. FG and XMM supervised the study. All authors read and approved the manuscript.

Funding

This work was supported by grants from Xinjiang Medical University's clinical medicine peak discipline (33-0104006020801#) and the special scientific research project of young medical scientific and technological talents of Xinjiang Uygur Autonomous region Health and Family Planning Commission (WJWY-202154).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate

The current research work received approval from the Academic Committee of The Third Clinical Medical College of Xinjiang Medical University (affiliated Tumor Hospital) and was carried out in accordance with the rules put forward in the Declaration of Helsinki. This study had the relevant exemption certificate of informed consent issued by the Academic Committee.

Consent for publication

All listed authors have actively participated in the study and have read and approved the submitted manuscript.

Competing Interests
The authors declare that they have no competing interests.

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.

2. Naga ChP, Gurram L, Chopra S, Mahantshetty U. The management of locally advanced cervical cancer. Curr Opin Oncol. 2018;30(5):323–9.

3. Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pacific J Cancer Prev. 2015;16(17):7401–7.

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

5. Orbegoso C, Murali K, Banerjee S. The current status of immunotherapy for cervical cancer. Reports Pract Oncol Radiother. 2018;23(6):580–8.

6. Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: An update. Expert Rev Anticancer Ther. 2016;16(1):83–98.

7. Bikfalvi A, Billottet C. The CC and CXC chemokines: Major regulators of tumor progression and the tumor microenvironment. Am J Physiol - Cell Physiol. 2020;318(3):C542–54.

8. Vinader V, Afarinkia K. The emerging role of CXC chemokines and their receptors in cancer. Future Med Chem. 2012;4(7):853–67.

9. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–72.

10. Zhu Q, Han X, Peng J, Qin H, Wang Y. The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol. 2012;43(6):699–713.

11. Cabrero-De Las Heras S, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol. 2018;24(32):4738–49.

12. Zeng Q, Sun S, Li Y, Li X, Li Z, Liang H. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment. Front Oncol. 2020;9:1555.

13. Chen E, Qin X, Peng K, Xu X, Li W, Cheng X, Tang C, Cui Y, Wang Z, Liu T. Identification of Potential Therapeutic Targets among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis. Cell Physiol Biochem. 2018;45(5):1731–46.

14. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia. 2004;67(1):10163–72.
15. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.

16. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (United States). 2017;19(8):649–58.

17. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):Pl1–1.

18. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(SUPPL. 2):214–20.

19. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.

20. Huang da W, Sherman BT, Zheng X, Yang J, Imamichi T, Stephens R, Lempicki RA. Extracting biological meaning from large gene lists with DAVID. Curr. Protoc. Bioinforma. 2009; (27):1–13.

21. Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, Yang S, Kim CY, Lee M, Kim E, et al. TRRUST v2: An expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–6.

22. Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics. Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–63.

23. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017. doi:10.1158/0008-5472.CAN-17-0307.

24. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, Cho KR. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res. 2007;77(21):e108–10.

25. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. Genes Chromosom Cancer. 2008;47(9):755–65.

26. Biewenga P, Buist MR, Moerland PD, Ver Loren van Themaat E, van Kampen AH, ten Kate FJ, Baas F. Gene expression in early stage cervical cancer. Gynecol. Oncol. 2008; 108(2008):520–526.

27. Small W, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileskin LR, Viswanathan AN, et al. Cervical cancer: A global health crisis. Cancer. 2017;123(13):2404–12.

28. López-Gómez M, Malmierca E, de Górgolas M, Casado E. Cancer in developing countries: The next most preventable pandemic. Crit Rev Oncol Hematol. 2013;88(1):117–22.
29. Zhu H, Zhu H, Tian M, Wang D, He J, Xu T. DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment. Front Genet. 2020;11(4):1–12.

30. Santoni M, Bracarda S, Nabissi M, Massari F, Conti A, Bria E, Tortora G, Santoni G, Cascinu S. CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. Biomed Res. Int. 2014;2014.

31. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005;16(6):593–609.

32. Lee NH, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Panreatology. 2018;18(7):705–16.

33. Poeta VM, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: New targets for cancer immunotherapy. Front Immunol. 2019;10(3):1664–3224.

34. Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri SK, Feirt N, Gordon R, Nagi CS, Wang Y, Entenberg D, et al. Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med. 2013;210(8):1509–28.

35. Kawai Y, Kaidoh M, Yokoyama Y, Sano K, Ohhashi T. Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. Cancer Sci. 2009;100(3):419–28.

36. Qiang WS, Fan Z, Peng LI. Relationship between expressions of chemokine CCR7,CCL21 and lymphatic metastasis in cervical carcinoma. Matern. Child Heal. Care China. 2010.

37. Chen XJ, Deng YR, Wang ZC, Wei WF, Zhou CF, Zhang YM, Yan RM, Liang LJ, Zhong M, Liang L, et al. Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment. Cell Death Dis. 2019;10(7):1–11.

38. Budczies J, Denkert C, Győrffy B, Schirmacher P, Stenzinger A. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Med Genomics. 2017;10(1):74.

39. Sarvaiya PJ, Guo D, Ulasov IV, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 2013;4(12):2171–85.

40. Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016;7(19):28697–710.

41. Roy I, Getschman AE, Volkman BF, Dwinell MB. Exploiting agonist biased signaling of chemokines to target cancer. Mol Carcinog. 2017;56(3):804–13.

42. McCall KD, Muccioli M, Benencia F. Toll-Like Receptors Signaling in the Tumor Microenvironment. 2020.

43. Tran TH, Tran TTP, Truong DH, Nguyen HT, Pham TT, Yong CS, Kim JO. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy. Acta Biomater. 2019;94:82–96.
44. Lu X, Yarbrough WG. Negative regulation of RelA phosphorylation: Emerging players and their roles in cancer. Cytokine Growth Factor Rev. 2015;26(1):7–13.

45. Giles KM, Brown RA, Ganda C, Podgorny MJ, Candy PA, Wintle LC, Richardson KL, Kalinowski FC, Stuart LM, Epis MR, et al. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget. 2016;7(22):31663–80.

46. Cartwright T, Perkins ND, Wilson CL. NFKB1: a suppressor of inflammation, ageing and cancer. FEBS J. 2016;283(10):1812–22.

47. Yang D, Zhang W, Liang J, Ma K, Chen P, Lu D, Hao W. Single cell whole genome sequencing reveals that NFKB1 mutation affects radiotherapy sensitivity in cervical cancer. Oncotarget. 2018;9(7):7332–40.

48. Deng YR, Chen XJ, Chen W, Wu LF, Jiang HP, Lin D, Wang LJ, Wang W, Guo SQ. Sp1 contributes to radioresistance of cervical cancer through targeting g2/m cell cycle checkpoint CDK1. Cancer Manag Res. 2019;11:5835–44.

49. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546–52.

50. Bommhardt U, Schraven B, Simeoni L. Beyond TCR signaling: Emerging functions of Lck in cancer and immunotherapy. Int J Mol Sci. 2019;20(14):1–18.

51. Chung EY, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, et al. PAK kinase inhibition has therapeutic activity in novel preclinical models of adult T-Cell leukemia/lymphoma. Clin. Cancer Res. 2019;25(12):3589–601.

52. Griffith JW, Sokol CL, Luster AD. Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity. Annu Rev Immunol. 2014;32(1):659–702.

53. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.

54. Aoki H, Ueha S, Shichino S, Ogiwara H, Hashimoto SI, Kakimi K, Ito S, Matsushima K. TCR repertoire analysis reveals mobilization of novel CD8 + T cell clones into the cancer-immunity cycle following anti-CD4 antibody administration. Front Immunol. 2019;10(1):1–13.

55. Knocke S, Fleischmann-Mundt B, Saborowski M, Manns MP, Kühnel F, Wirth TC, Woller N. Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 + T Cell Responses against Cancer. Cell Rep. 2016;17(9):2234–46.

56. Ding H, Cai J, Mao M, Fang Y, Huang Z, Jia J, Li T, Xu L, Wang J, Zhou J, et al. Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells. Apmis. 2014;122(11):1059–69.

Figures
Figure 1

mRNA levels of CXC chemokines in cervical cancer (ONCOMINE). It shows the numbers of datasets with statistically significant mRNA over-expression (red) or down-regulated expression (blue) of CXC chemokines.
Figure 2

The expression of distinct CXC chemokines in CC tissues and adjacent normal cervical tissues. a The color of red represents high expression, while green color shows low expression between cervical tumor and normal tissues in the GEPIA database. b-g The color of blue represents normal cervical tissues, red color represents CC tissue in the UALCAN database. ** $p < 0.01$, *** $p < 0.001$.
Figure 3

Expression of CXC chemokines between CC tissues and normal tissues were analyzed by Q-PCR. a CXCL9. b CXCL10. c CXCL11. d CXCL13. * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 4

Representative immunohistochemistry images of distinct CXC chemokines in cervical cancer tissues and normal cervical tissues.
Figure 5

The prognostic value of different expressed CXC chemokines in survival curve. a CXCL1 (OS). b CXCL2 (OS). c CXCL3 (OS). d CXCL4 (OS). e CXCL5 (OS). f CXCL8 (OS). g CXCL3 (DFS).
Figure 6

Genetic alteration, neighbor gene network and interaction analyses of different expressed CXC chemokines. a CXC chemokines’ mutation analysis in CC (cBioPortal). b-c Protein-protein interaction network of different expressed CXC chemokines (STRING and GeneMANIA).
Figure 7

Analysis of GO and KEGG (DAVID). a Bar-plot of GO enrichment in biological process terms, cellular component terms and molecular function terms. b Bar-plot of KEGG enriched terms.
Figure 8

The correlation between different expressed CXC chemokines and immune cell infiltration (TIMER).